The top documents tagged [response duration]

[Day 2] Center Presentation: WFP
Technology [Day 2] Center Presentation: WFP

466 views

07 state of the art of the management of advanced and recurrent ovarian cancer
Health & Medicine 07 state of the art of the management of advanced and recurrent ovarian cancer

440 views

Dr. Gopichand Pendurti M.B.B.S ACTIVITY OF RITUXIMAB AND OFATUMUMAB AGAINST MANTLE CELL LYMPHOMA(MCL) IN VITRO IN MCL CELL LINES BY COMPLEMENT DEPENDENT
Documents Dr. Gopichand Pendurti M.B.B.S ACTIVITY OF RITUXIMAB AND OFATUMUMAB AGAINST MANTLE CELL LYMPHOMA(MCL) IN VITRO IN MCL CELL LINES BY COMPLEMENT DEPENDENT

213 views

Multiple Myeloma: ASH 2005 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine
Documents Multiple Myeloma: ASH 2005 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine

221 views

Steele Taylor presents: A Neuro-Endocrine Approach to The Obstetric and Pediatric Applications of Tactile-Kinesthetic Stimulation Therapy questions/complaints:
Documents Steele Taylor presents: A Neuro-Endocrine Approach to The Obstetric and Pediatric Applications of Tactile-Kinesthetic Stimulation Therapy questions/complaints:

222 views

Differential Reinforcement & Differential Punishment Chapter 7
Documents Differential Reinforcement & Differential Punishment Chapter 7

244 views

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent
Documents Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent

216 views

STN 125011 Tositumomab Therapeutic Regimen (TTR) [tositumomab plus I-131 tositumomab] Oncologic Drugs Advisory Committee December 17, 2002
Documents STN 125011 Tositumomab Therapeutic Regimen (TTR) [tositumomab plus I-131 tositumomab] Oncologic Drugs Advisory Committee December 17, 2002

214 views

Update: Non-Hodgkin’s Lymphoma 20082008. ICML 2008: Update on non-Hodgkin’s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients
Documents Update: Non-Hodgkin’s Lymphoma 20082008. ICML 2008: Update on non-Hodgkin’s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients

233 views

New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance
Documents New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance

217 views

Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi
Documents Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi

233 views

FDA Review : Cisplatin / Epinephrine Gel (CEG) in the Treatment of Head and Neck Cancer
Documents FDA Review : Cisplatin / Epinephrine Gel (CEG) in the Treatment of Head and Neck Cancer

219 views